source
- Scribe Therapeutics launches $129M IPO, kicking off second-half biotech listing spreeScribe Therapeutics, a nine-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna, announced its initial public offering. The company priced the IPO at about $128.7 million, raising roughl…
- Scribe Therapeutics upsizes IPO to $128.7 million to fund lipid-lowering gene therapyScribe Therapeutics announced pricing its initial public offering at $128.7 million, surpassing the $96 million target it had set earlier in the week. The company sold 8.6 million shares at $15 ea…